165 related articles for article (PubMed ID: 27026431)
1. Examining the clinical course of genotype 1 chronic hepatitis C patients treated with the cosmos regimen: including patients with advanced liver disease and East Asian ancestry.
Roytman M; Ramkissoon R; Wu C; Hong L; Trujillo R; Huddleston L; Poerzgen P; Seto T; Wong L; Tsai N
Hepatol Int; 2016 Jul; 10(4):616-23. PubMed ID: 27026431
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of ledipasvir/sofosbuvir with or without ribavirin in hepatitis C genotype 1 patients including those with decompensated cirrhosis who failed prior treatment with simeprevir/sofosbuvir.
Modi AA; Nazario HE; Gonzales GR; Gonzalez SA
Aliment Pharmacol Ther; 2018 May; 47(10):1409-1415. PubMed ID: 29569736
[TBL] [Abstract][Full Text] [Related]
3. Simeprevir and sofosbuvir with or without ribavirin to treat recurrent genotype 1 hepatitis C virus infection after orthotopic liver transplantation.
Crittenden NE; Buchanan LA; Pinkston CM; Cave B; Barve A; Marsano L; McClain CJ; Jones CM; Marvin MR; Davis EG; Kuns-Adkins CB; Gedaly R; Brock G; Shah MB; Rosenau J; Cave MC
Liver Transpl; 2016 May; 22(5):635-43. PubMed ID: 26915588
[TBL] [Abstract][Full Text] [Related]
4. Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 in patients with cirrhosis.
Aqel BA; Pungpapong S; Leise M; Werner KT; Chervenak AE; Watt KD; Murphy JL; Ryland K; Keaveny AP; McLemore R; Vargas HE
Hepatology; 2015 Oct; 62(4):1004-12. PubMed ID: 26096332
[TBL] [Abstract][Full Text] [Related]
5. Safety and Efficacy of Simeprevir/Sofosbuvir in Hepatitis C-Infected Patients With Compensated and Decompensated Cirrhosis.
Saxena V; Nyberg L; Pauly M; Dasgupta A; Nyberg A; Piasecki B; Winston B; Redd J; Ready J; Terrault NA
Hepatology; 2015 Sep; 62(3):715-25. PubMed ID: 26033798
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of simeprevir plus sofosbuvir with or without ribavirin in patients with decompensated genotype 1 hepatitis C cirrhosis.
Modi AA; Nazario H; Trotter JF; Gautam M; Weinstein J; Mantry P; Barnes M; Habib A; McAfee J; Teachenor O; Tujague L; Gonzalez S
Liver Transpl; 2016 Mar; 22(3):281-6. PubMed ID: 26335142
[TBL] [Abstract][Full Text] [Related]
7. Simeprevir and Sofosbuvir (SMV-SOF) for 12 Weeks for the Treatment of Chronic Hepatitis C Genotype 1 Infection: A Real World (Transplant) Hepatology Practice Experience.
Pillai AA; Wedd J; Norvell JP; Parekh S; Cheng N; Young N; Spivey JR; Ford R
Am J Gastroenterol; 2016 Feb; 111(2):250-60. PubMed ID: 26832650
[TBL] [Abstract][Full Text] [Related]
8. Sofosbuvir-Based Regimens for Chronic Hepatitis C in a Well-Insured U.S. Population: Patient Characteristics, Treatment Adherence, Effectiveness, and Health Care Costs, 2013-2015.
Yin S; Barker L; White JZ; Jiles RB
J Manag Care Spec Pharm; 2019 Feb; 25(2):195-210. PubMed ID: 30698086
[TBL] [Abstract][Full Text] [Related]
9. Sofosbuvir and ribavirin for genotype 2 HCV infected patients with cirrhosis: A real life experience.
Mangia A; Susser S; Piazzolla V; Agostinacchio E; De Stefano G; Palmieri V; Spinzi G; Carraturo I; Potenza D; Losappio R; Arleo A; Miscio M; Santoro R; Sarrazin C; Copetti M
J Hepatol; 2017 Apr; 66(4):711-717. PubMed ID: 27965158
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness and safety of simeprevir-based regimens for hepatitis C in Italy: The STIly observational study.
Gaeta GB; Aghemo A; Menzaghi B; D'Offizi G; Giorgini A; Hasson H; Brancaccio G; Palma M; Termini R;
Medicine (Baltimore); 2018 Jul; 97(27):e11307. PubMed ID: 29979400
[TBL] [Abstract][Full Text] [Related]
11. Real-World Single-Center Experience with Sofosbuvir-Based Regimens for the Treatment of Chronic Hepatitis C Genotype 1 Patients.
Shin HP; Burman B; Kozarek RA; Zeigler A; Wang C; Lee H; Zehr T; Edwards AM; Siddique A
Gut Liver; 2017 Sep; 11(5):711-720. PubMed ID: 28651301
[TBL] [Abstract][Full Text] [Related]
12. High Efficacy and Safety of Flat-Dose Ribavirin Plus Sofosbuvir/Daclatasvir in Genotype 3 Cirrhotic Patients.
Pellicelli A; Messina V; Giannelli V; Distefano M; Palitti VP; Vignally P; Tarquini P; Izzi A; Moretti A; Babudieri S; Dell'Isola S; Marignani M; Scifo G; Iovinella V; Cariti G; Pompili M; Candilo FD; Fontanella L; Ettorre GM; Vennarecci G; Ippolito AM; Barbarini G
Gut Liver; 2020 May; 14(3):357-367. PubMed ID: 30970444
[TBL] [Abstract][Full Text] [Related]
13. Real-World Study on Sofosbuvir-based Therapies in Asian Americans With Chronic Hepatitis C.
Pan CQ; Tiongson BC; Hu KQ; Han SB; Tong M; Chu D; Park J; Lee TP; Bhamidimarri KR; Ma X; Xiao PY; Mohanty SR; Wang D
J Clin Gastroenterol; 2019 Feb; 53(2):147-154. PubMed ID: 29912759
[TBL] [Abstract][Full Text] [Related]
14. Real life efficacy of ledipasvir/sofosbuvir in hepatitis C genotype 4-infected patients with advanced liver fibrosis and decompensated cirrhosis.
Sanai FM; Altraif IH; Alswat K; AlZanbagi A; Babatin MA; AlMousa A; Almutairi NH; Aljawad MS; Alghamdi AS; Aljumah AA; Alalwan AM; Al-Hamoudi WK; Assiri AM; Dahlan Y; Alsahafi A; Alothmani HS; AlSaleemi MS; Mousa WA; Albenmousa A; Awny A; Albiladi H; Abdo AA; AlGhamdi H
J Infect; 2018 Jun; 76(6):536-542. PubMed ID: 29742470
[TBL] [Abstract][Full Text] [Related]
15. Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1-infected patients without cirrhosis: OPTIMIST-1, a phase 3, randomized study.
Kwo P; Gitlin N; Nahass R; Bernstein D; Etzkorn K; Rojter S; Schiff E; Davis M; Ruane P; Younes Z; Kalmeijer R; Sinha R; Peeters M; Lenz O; Fevery B; De La Rosa G; Scott J; Witek J
Hepatology; 2016 Aug; 64(2):370-80. PubMed ID: 26799692
[TBL] [Abstract][Full Text] [Related]
16. Sofosbuvir and simeprevir in hepatitis C genotype 1-patients with end-stage renal disease on haemodialysis or GFR <30 ml/min.
Nazario HE; Ndungu M; Modi AA
Liver Int; 2016 Jun; 36(6):798-801. PubMed ID: 26583882
[TBL] [Abstract][Full Text] [Related]
17. HEPATITIS C TREATMENT OF RENAL TRANSPLANT AND CHRONIC KIDNEY DISEASE PATIENTS: EFFICACY AND SAFETY OF DIRECT-ACTING ANTIVIRAL REGIMENS CONTAINING SOFOSBUVIR.
Michels FBL; Amaral ACC; Carvalho-Filho RJ; Vieira GA; Souza ALDS; Ferraz MLG
Arq Gastroenterol; 2020; 57(1):45-49. PubMed ID: 32294735
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of 6 or 8 weeks of simeprevir, daclatasvir, sofosbuvir for HCV genotype 1 infection.
Sulkowski MS; Feld JJ; Lawitz E; Felizarta F; Corregidor AM; Khalid O; Ghalib R; Smith WB; Van Eygen V; Luo D; Vijgen L; Gamil M; Kakuda TN; Ouwerkerk-Mahadevan S; Van Remoortere P; Beumont M
J Viral Hepat; 2018 Jun; 25(6):631-639. PubMed ID: 29274193
[TBL] [Abstract][Full Text] [Related]
19. Safety and Effectiveness of Ledipasvir and Sofosbuvir, With or Without Ribavirin, in Treatment-Experienced Patients With Genotype 1 Hepatitis C Virus Infection and Cirrhosis.
Lim JK; Liapakis AM; Shiffman ML; Lok AS; Zeuzem S; Terrault NA; Park JS; Landis CS; Hassan M; Gallant J; Kuo A; Pockros PJ; Vainorius M; Akushevich L; Michael L; Fried MW; Nelson DR; Ben-Ari Z;
Clin Gastroenterol Hepatol; 2018 Nov; 16(11):1811-1819.e4. PubMed ID: 29306043
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of sofosbuvir/simeprevir plus flat dose ribavirin in genotype 1 elderly cirrhotic patients: A real-life study.
Pellicelli AM; Pace Palitti V; Vignally P; Ceccherini-Silberstein F; Siciliano M; Giannelli V; Moretti A; Tarquini P; Scifo G; Messina V; Ascione A; Izzi A; Marignani M; D'Ambrosio C; Fondacaro L; Ettorre GM; Ialongo P; Sacco R; Perno CF; Barbarini G;
Liver Int; 2017 May; 37(5):653-661. PubMed ID: 27782373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]